Skip to main content
Premium Trial:

Request an Annual Quote

Gentel to Collaborate with SCOPE Consortium

NEW YORK (GenomeWeb News) – Gentel Biosciences will collaborate with an international consortium focused on developing biomarkers for pregnancy complications, the company said.

The Screening for Pregnancy Endpoints (SCOPE) Study is establishing a pregnancy biobank that will be used to research tests that can predict major diseases of late-stage pregnancy, which affect 19 percent of worldwide pregnancies, the company said.

"Our goal is to develop a high performance screening test for preeclampsia" using Gentel's Apix Array platform, SCOPE Project Leader and University of Adelaide Professor Robyn North said in a statement.

Madison, Wis.-based GenTel will develop and validate a quantitative multiplex immunoassay using its microarray technologies to measure a large panel of analytes.

Financial terms of the agreement were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.